Kirit Ardeshna
Overview
Explore the profile of Kirit Ardeshna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morschhauser F, Dahiya S, Palomba M, Garcia-Sancho A, Reguera Ortega J, Kuruvilla J, et al.
Nat Med
. 2024 Jul;
30(8):2374.
PMID: 38982297
No abstract available.
2.
Morschhauser F, Dahiya S, Palomba M, Garcia-Sancho A, Reguera Ortega J, Kuruvilla J, et al.
Nat Med
. 2024 Jun;
30(8):2199-2207.
PMID: 38830991
An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24 months (POD24) from first-line immunochemotherapy or disease...
3.
Lenz G, Hawkes E, Verhoef G, Haioun C, Lim S, Heo D, et al.
Leukemia
. 2024 Jan;
38(2):469-472.
PMID: 38200221
No abstract available.
4.
Opat S, Tedeschi A, Hu B, Linton K, McKay P, Leitch S, et al.
Blood Adv
. 2023 Sep;
7(22):6801-6811.
PMID: 37682792
The primary analysis of MAGNOLIA, an open-label, single-arm, multicenter, phase 2 study, demonstrated that the next-generation Bruton tyrosine kinase (BTK) inhibitor zanubrutinib provided a high overall response rate (ORR) in...
5.
Kuhnl A, Roddie C, Kirkwood A, Tholouli E, Menne T, Patel A, et al.
Br J Haematol
. 2022 Apr;
198(3):492-502.
PMID: 35485402
CD19 CAR-T have emerged as a new standard treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). CAR-T real-world (RW) outcomes published to date suggest significant variability across countries. We provide...
6.
Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, et al.
Clin Cancer Res
. 2021 Sep;
27(23):6323-6332.
PMID: 34526366
Purpose: Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We evaluated the efficacy and safety of zanubrutinib,...
7.
Davies A, Barrans S, Burton C, Mercer K, Caddy J, Chinnery F, et al.
F1000Res
. 2020 Oct;
9:941.
PMID: 33093947
Over 13,000 new cases of non-Hodgkin's lymphoma (NHL) are diagnosed in the UK, with approximately 4,900 attributable deaths each year. Diffuse Large B-cell Lymphoma (DLBCL) is the most common NHL...
8.
McNamara C, Montoto S, Eyre T, Ardeshna K, Burton C, Illidge T, et al.
Br J Haematol
. 2020 Jun;
191(3):363-381.
PMID: 32579717
No abstract available.
9.
Lenz G, Hawkes E, Verhoef G, Haioun C, Lim S, Heo D, et al.
Leukemia
. 2020 Feb;
34(8):2184-2197.
PMID: 32060403
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have adverse outcomes. We evaluated the efficacy and safety of the phosphatidylinositol 3-kinase inhibitor copanlisib in patients with relapsed/refractory DLBCL and assessed...
10.
Townsend W, Leong S, Hoskin P, Diez P, Patrick P, Linch D, et al.
Br J Haematol
. 2019 Nov;
189(1):128-132.
PMID: 31710702
This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk-stratified protocol in young adults (18-30 years) with classical Hodgkin Lymphoma. The primary end-point...